← Back to GYRE

Gyre Therapeutics, Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 07/08/2026Mar 2026Filed 07/08/2026Sep 2025Filed 07/11/2025Jun 2025Filed 07/08/2026Mar 2025Filed 07/08/2026Sep 2024Filed 07/11/2025Jun 2024Filed 07/11/2025Mar 2024Filed 07/11/2025
$29$23$31$30$22$25$25$27
−$14−$19$5.9−$2.2$4.9$2.9$4.5$9.9
−$0.12−$0.10$0.03−$0.03$0.00$0.01$0.01$0.03
1019110489102103102103

Trend

Revenue

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.